ANTITOXIN

Executive Summary

ANTITOXIN GmbH, founded in 1966 and headquartered in Munich, Germany, is a private company specializing in the production of blood typing antisera. Its comprehensive portfolio includes ABO and Rh system reagents (Anti-D, Anti-C, Anti-E, etc.) as well as rare antisera such as Anti-P1, Anti-M/N, Anti-Kell, and others. The company serves transfusion medicine and blood banks, providing essential reagents for safe blood transfusions. Despite its long history, ANTITOXIN remains a niche player with no disclosed funding rounds or valuation, suggesting a stable, privately held operation. Its website and publicly available information indicate a focus on traditional diagnostic products rather than novel antibody discoveries or infectious disease therapeutics, despite its categorization in Antibodies and Infectious Disease.

Upcoming Catalysts (preview)

• Q3 2026Expansion of rare sera product line to support emerging blood group genotyping50% success
• TBDPartnership with a global diagnostics distributor to enter new geographic markets30% success
• TBDRegulatory approval for an automated blood typing system incorporating antisera20% success